Original Research and the Latest News

How Next-Generation Probability of Success Forecasting Can Improve Clinical Trial Accuracy by 44%

Unlocking Next-Gen POS Forecasting for Biopharma Success In the high-stakes world of biopharma, advanced Probability of Success (POS) forecasting can revolutionize the landscape of clinical trials. By adopting next-gen POS forecasting models, companies can...

Not Your Grandparents’ Probability of Success Forecasts

Redefining Probability of Success in Pharma: A Data-Driven Revolution In the world of pharmaceutical strategic planning and analytics, traditional Probability of Success (POS) forecasts are a familiar, yet often frustrating approach to assessing clinical risk. While...

Who’s Winning the Pharmaceutical R&D Pipeline Race in 2025

The leaders, the contenders, and the strategies for success As we approach the 4th quarter of 2025, let’s review where the pharmaceutical industry’s leading companies rank in terms of overall pipeline strength.Roche, AstraZeneca, and Bristol-Myers Squibb sit in a...

Clinical Trial Success Rates: What Makes Some Companies Stand Out?

Our comprehensive analysis of over 30,000 clinical trials across more than 4,000 biopharmaceutical companies reveals significant variations in clinical trial success rates. This disparity exists even among trials in the same phase and targeting the same disease,...

Recent Posts

Recent Tweets

$ERAS

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

More Info: https://pryzm.ozmosi.com/product/34229

$ALKS +nan% today

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

More Info: https://pryzm.ozmosi.com/product/31577

$BRCTF +nan% today

New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease

More Info: https://pryzm.ozmosi.com/product/16901

$BMRN +nan% today

U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia

More Info: https://pryzm.ozmosi.com/product/2395

Load More

Get Started with OZMOSI

We synthesize and process insights, delivering what you need quickly, effectively, and efficiently.

600 Warren Ave,
Spring Lake, NJ 07762